Imatinib mesylate for targeting the platelet-derived growth factor β receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer - A dose-escalation phase I trial

Cancer

Volumn 109, Issue 9, 2007, Pages 1897-1904

  Al Batran, Salah Eddin ^a   Atmaca, Akin ^a   Schleyer, Eberhard ^b   Pauligk, Claudia ^a   Hosius, Christian ^c   Ehninger, Gerhard ^d   Jäger, Elke ^a  

^a KRANKENHAUS NORDWEST   (Germany)

^b Carl von Basedow Hospital   (Germany)

^c Novartis Pharma   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Cancer; Gastrointestinal; Imatinib; Platelet derived growth factor receptor

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GAMMA GLUTAMYLTRANSFERASE; IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

ADULT; AGED; ANEMIA; ARTICLE; ASCITES; BILE DUCT CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; FLUID RETENTION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIGESTIVE SYSTEM NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-SIS; PYRIMIDINES;

EID: 34247565935     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22622     Document Type: Article

References (16)

1. Broxterman HJ, Lankelma J, Hoekman K. Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences. Drug Resist Update. 2003;6:111-127.
2. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng. 1999;1:241-263.
3. Pietras K. Increasing tumor uptake of anticancer drugs with imatinib. Semin Oncol. 2004;31(2 suppl 6):18-23.
4. Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001;61:2929-2934.
5. Pietras K, Rubin K, Sjoblom T, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002;62:5476-5484.
6. Pietras K, Stumm M, Hubert M, et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res. 2003;9(10 pt 1):3779-3787.
7. Al-Batran S, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol. 2004;22:658-663.
8. Al-Batran SE, Hartmann JT, Probst S, et al. A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP). J Clin Oncol. 2006; 24:18S. Abstract 4016.
9. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
10. Schleyer E, Pursche S, Kohne CH, et al. Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;799: 23-36.
11. Falcone A, Masi G, Allegrini G, et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol. 2002;20:4006-4014.
12. Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist. 2004;9:271-281.
13. Briasoulis E, Pavlidis N. Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. Oncologist. 2001;6:153-156.
14. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
15. Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer. 1997;33(suppl 1):S18-S22.
16. George S, Desai J, Paul Eder J, et al. Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours. Eur J Cancer. 2006;42:864-870.